AI model for diagnosing lymph node metastasis in nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study develops an artificial intelligence model to assist in diagnosing lymph node metastasis in patients with nasopharyngeal carcinoma. The model utilizes MRI images of the lymph nodes and surrounding areas, analyzing features before and after chemotherapy to track changes. It aims to automatically identify lymph nodes and predict the likelihood of metastasis based on both MRI and pathological data. The approach combines advanced imaging techniques with AI to enhance diagnostic accuracy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The primary lesion was pathologically confirmed as nasopharyngeal carcinoma (WHO classification is I, II and III);
2. MRI scan was performed at the initial diagnosis (before anti-tumor treatment), and transverse and coronal MRI images before treatment were available, including T1-weighted, T2-weighted and T1-enhanced scanning sequences.
3. PET/CT scan was performed at the initial diagnosis (before anti-tumor treatment)
4. When MRI and PET/CT were inconsistent in judging the benign or malignant nature of lymph nodes, the patient agreed to undergo cervical lymph node puncture and pathological examination.

Exclusion Criteria:

1. The patient has undergone cervical lymph node radiotherapy for any reason
2. Combined with other malignant tumors

Where it's running

• Department of Radiation Oncology, Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nanocrystalline Megestrol Acetate to Help Appetite During Chemoradiotherapy in Nasopharyngeal Carcinoma

  This phase 3 trial tests whether taking nanocrystalline megestrol acetate can help people with nasopharyngeal carcinoma who are receiving chemoradiotherapy to keep their appetite and weight better than placebo.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT07796789

• Becotatug Vedotin plus Anti-PD-1 as maintenance for recurrent/metastatic NPC

  This phase 3 trial tests whether adding becotatug vedotin to an anti-PD-1 therapy as maintenance can help people with recurrent or metastatic nasopharyngeal cancer who have stable disease after initial treatment.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07705243

• Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer

  This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.

  Recruiting Phase 1 West China Hospital · Chengdu, China · NCT07625423

• Maintenance immunotherapy with deferred salvage radiotherapy after response to chemoimmunotherapy in recurrent nasopharyngeal cancer

  This study tests whether continuing immunotherapy and delaying salvage radiotherapy after an initial chemoimmunotherapy response can help people with unresectable recurrent nasopharyngeal cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Fuzhou, Fujian and 3 other locations · NCT07528183

• Becotatug vedotin added to radiation and adjuvant therapy for locally advanced nasopharyngeal cancer with a poor response to induction chemo‑immunotherapy

  This will test whether adding becotatug vedotin during radiation and afterward helps people with locally advanced nasopharyngeal cancer who had a suboptimal response to induction chemotherapy combined with immunotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07496190

• IMRT-only treatment for stage IB nasopharyngeal cancer without high-risk features

  This trial will test whether IMRT alone can control stage IB nasopharyngeal cancer without high-risk features in adults aged 18–70.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian · NCT07376603

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.